ReviewFrontiers in artificial intelligence2026
Autofluorescence and deep learning in early disease detection: biological foundations, clinical applications, and future directions.
Review in Frontiers in artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autofluorescence (AF) imaging enables label-free visualization of tissue metabolism and microenvironmental alterations, while deep learning (DL) provides powerful tools to decode its complex optical signatures. Their integration has emerged as a promising framework for functional and biologically informed disease assessment. Recent studies demonstrate that AF-DL approaches improve lesion detection, intraoperative guidance, and early therapeutic response evaluation across multiple organ systems. By leveraging multidimensional spectral, temporal, and spatial features, DL mitigates the intrinsic variability and limited specificity of standalone AF imaging. This review summarizes current diagnostic, prognostic, and surgical applications of AF-DL integration, with particular emphasis on model interpretability, generalizability, and biological relevance. Key challenges, including device dependence, dataset heterogeneity, annotation burden, and regulatory considerations, are critically discussed. Finally, future directions are proposed toward standardized acquisition, prospective multicenter validation, and clinically integrated workflows. By bridging intrinsic tissue biochemistry with data-driven intelligence, AF-DL integration offers a new class of functional imaging biomarkers with significant potential for precision diagnosis, surgery, and treatment monitoring.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.